Hepatitis B Topics HBV Treatment Drug Advisories & Warnings
FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 04 December 2012 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.
Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 27 December 2011 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for the nucleoside analog telbivudine (Tyzeka), indicating that it should not be used with pegyalted interferon alfa-2a (brand name Pegasys) for the treatment of hepatitis B because the combination can cause peripheral neuropathy, or nerve damage.
Telbivudine Label Adds Resistance Warning
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 05 April 2011 07:01
- Written by Press Release
Package labeling for the hepatitis B drug telbivudine (Tyzeka) was recently changed to add information about the risk of drug resistance and a recommendation for monitoring after 6 months of treatment.
Web Design and Development by